Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Arin Tactical Tail Risk ETF

95.32
0.0000
Volume:12
Turnover:1.14K
Market Cap:111.44M
PE:- -
High:95.32
Open:95.32
Low:95.32
Close:95.32
52wk High:95.59
52wk Low:45.10
Shares:1.17M
Float Shares:1.17M
Volume Ratio:0.02
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

GlobeNewswire
·
Jul 22

Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure

Simply Wall St.
·
Jul 10

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

GlobeNewswire
·
Jul 02

DKSH Partners with BridgeBio to Distribute ATTR-CM Drug in Key Asia-Pacific Markets

TIPRANKS
·
Jun 11

AstraZeneca Advances Dual ATTR-CM Therapy With New Phase IIb Trial

TIPRANKS
·
Jun 11

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

GlobeNewswire
·
May 11

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

GlobeNewswire
·
May 06

AstraZeneca Targets Early Detection in China With New ATTR Heart Disease Study

TIPRANKS
·
Apr 15

Assessing BridgeBio Pharma (BBIO) Valuation After Key ATTR-CM And LGMD2I/R9 Milestones

Simply Wall St.
·
Apr 13

BridgeBio: Advancing First-in-Class LGMD Therapy and Blockbuster ATTR Franchise Underpin Reiterated Buy and $100 Target

TIPRANKS
·
Mar 31

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

GlobeNewswire
·
Mar 31

Alnylam Pharmaceuticals: Durable ATTR Growth and Amvuttra Momentum Support Buy Rating and Upside Potential

TIPRANKS
·
Mar 25